- Home
- III vs GNLX Comparison
III vs GNLX Comparison
Compare III & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | III | GNLX |
|---|---|---|
| Founded | 2006 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 251.4M | 202.4M |
| IPO Year | 2007 | 2023 |
Fundamental Metrics
Financial Performance| Metric | III | GNLX |
|---|---|---|
| Price | $6.04 | $4.36 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $7.00 | ★ $19.75 |
| AVG Volume (30 Days) | ★ 320.4K | 140.8K |
| Earning Date | 11-03-2025 | 11-05-2025 |
| Dividend Yield | ★ 3.04% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.19 | N/A |
| Revenue | ★ $241,289,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.63 | N/A |
| P/E Ratio | $31.11 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.95 | $1.99 |
| 52 Week High | $6.45 | $8.54 |
Technical Indicators
Market Signals| Indicator | III | GNLX |
|---|---|---|
| Relative Strength Index (RSI) | 59.43 | 40.94 |
| Support Level | $5.85 | $4.20 |
| Resistance Level | $6.05 | $4.37 |
| Average True Range (ATR) | 0.14 | 0.25 |
| MACD | -0.01 | 0.06 |
| Stochastic Oscillator | 56.06 | 46.90 |
Price Performance
Historical ComparisonAbout III Information Services Group Inc.
Information Services Group Inc is a U.S.-based technology insight, market intelligence, and advisory services firm. It principally offers digital transformation services, such as automation and cloud & data analytics; managed governance; network carrier services; technology plan and operations design; changes management; market intelligence & technology research and analysis. It operates in one segment, fact-based sourcing advisory services. Its geographical segments are the Americas, Europe, and Asia-pacific, out of which maximum revenue is derived from Americas.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.